Day: October 9, 2020

By [email protected]_84

HHS Testing Czar Rips Nevada for Stopping Rapid Tests in Nursing Homes

WASHINGTON — Nevada public health officials’ recent actions preventing nursing homes from using rapid screening tests for COVID-19 are “unjustified” and don’t follow the science on testing, Department of Health and Human Services (HHS) “testing czar” Adm. Brett Giroir, MD, said Friday.

The state’s actions are “not scientifically valid. They must cease their prohibition immediately,” Giroir said on a phone call with reporters. “If you need technical support,” he told the nursing homes, “we are enthusiastic to do more. Lives are at stake and our administration is not going to allow action to risk our seniors or any other vulnerable or underserved population.”

Letter Sent to Nursing Homes

On October 2, the Nevada Department of Health and Human Services sent a letter to healthcare providers and long-term care facilities, noting that the Centers for Medicare & Medicaid Services had sent point-of-care antigen tests to nursing homes across the country —

Read More
By [email protected]_84

Cervical Cancer Therapeutics Market | Rising Prevalence of Cervical Cancer to Boost the Market Growth

The global cervical cancer therapeutics market size is poised to grow by USD 1.06 billion during 2020-2024, progressing at a CAGR of over 7% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.

This press release features multimedia. View the full release here:

Technavio has announced its latest market research report titled Global Cervical Cancer Therapeutics Market 2020-2024 (Graphic: Business Wire)

There has been an increase in the prevalence of several female health conditions such as breast cancer and gynecological cancer, including cervical cancer. As a result, various organizations across the globe are conducting health initiatives towards the prevention

Read More
By [email protected]_84

The New England Journal of Politics, Part II

The entrance to the editorial offices of the New England Journal of Medicine in Boston.



The New England Journal of Medicine (NEJM) his week published an editorial denouncing “dangerously incompetent” leadership in Washington on the pandemic and all but endorsing Joe Biden for President. This will go down well in all the right precincts. But then please don’t complain if half of America suspects that science is increasingly politicized.

The editorial recites the government’s well-known failures in managing the coronavirus, such as the initial struggles to roll out testing and hand out enough protective equipment. We can’t disagree with that, but the editors go on to extol China’s virus management, conveniently ignoring its early cover-up and manipulation of the World Health Organization. Why are American elites so enamored of authoritarian command and control? The

Read More
By [email protected]_84

‘I’m mad I was lied to’

Dr. Gao Jye Teh is a dentist based in Malaysia who, like many professionals over the course of quarantine, decided to join TikTok to spread dental awareness in easy, 60-second videos.

He only joined the platform in September, but one of Dr. Gao’s videos on toothpaste has gone viral already — clocking in at over 6 million views.

“Are you using the right amount of toothpaste,” Dr. Gao asks in the caption. According to the comments (and this writer’s personal experience), the answer is no.

Dr. Gao explains in the video that the amount of toothpaste shown in commercials — you know, that perfect curly toothpaste swish — is way, way too much. You actually only need a dot the size of a pea.

For young kids, particularly those around the age of 3 years old, you only need a very thin smear.

“Nah if my gums ain’t bleeding and

Read More
By [email protected]_84

Trump official says vaccine expected starting in January

A Trump administration official leading the response to the coronavirus pandemic says the U.S. can expect delivery of a vaccine starting in January 2021, despite statements from the president that inoculations could begin this month.

And a growing, bipartisan chorus of lawmakers, experts and public health officials says the country is ill prepared for a projected winter surge of COVID-19.

Dr. Robert Kadlec said in an email Friday that the administration “is accelerating production of safe and effective vaccines … to ensure delivery starting January 2021.” Kadlec is the Department of Health and Human Services’ assistant secretary of preparedness and response. HHS says a vaccine could be approved before the end of the year but will take time to distribute.

President Donald Trump has said at rallies, debates and press conferences that a vaccine could arrive within weeks. “We think we can start sometime in October,” Trump said at a

Read More
By [email protected]_84

The Hill’s Campaign Report: Trump campaigns on Rush Limbaugh show l Democrats question Trump’s mental fitness l Coronavirus stimulus in doubt before election

Welcome to The Hill’s Campaign Report, your daily rundown on all the latest news in the 2020 presidential, Senate and House races. Did someone forward this to you? Click here to subscribe.

We’re Julia Manchester, Max Greenwood and Jonathan Easley. Here’s what we’re watching today on the campaign trail:


Happy Friday! From talk of invoking the 25th Amendment to President TrumpDonald John TrumpBiden campaign raises over M on day of VP debate Trump chastises Whitmer for calling him ‘complicit’ in extremism associated with kidnapping scheme Trump says he hopes to hold rally Saturday despite recent COVID-19 diagnosis MORE’s two-hour call into the Rush Limbaugh show, it’s been another chaotic day in Washington to say the least.

Let’s get you up to speed.

The day kicked off with Democrats rolling out legislation that would establish a panel to examine a sitting president’s ability to perform

Read More
By [email protected]_84

Vericiguat Benefits Even With High Adherence to HFrEF Meds

Vericiguat (Merck/Bayer), among the latest drugs to gain cred in heart failure (HF) with reduced ejection fraction (HFrEF), significantly benefits patients who are highly adherent to standard-of-care (SOC) HF meds, suggests a new VICTORIA trial analysis.

The novel agent seemed to improve the primary endpoint on top of the entire slate of SOC agents, individually and when they were combined as guidelines recommend.

The research, reported earlier this week at the Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting 2020, also hinted at potential clinical-outcomes synergy between vericiguat and a drug class that is a cornerstone of HF medical management.

The findings argue against misgivings that recent and any future additions to the HF armamentarium could be therapeutically redundant or add to patients’ daily pill burden and potential for side effects without much incremental benefit.

There is as yet little evidence for such an effect; also, vericiguat and

Read More
By [email protected]_84

Coronavirus antibody drugs won’t end U.S. epidemic

Dr. Scott Gottlieb told CNBC on Friday that antibody drugs are likely to be important treatments for the coronavirus, but he cautioned against considering them a panacea for the nation’s Covid-19 outbreak.

The former U.S. Food and Drug Administration commissioner said the lack of supply means not every person who becomes diagnosed with the coronavirus will be able to receive an antibody treatment — should the FDA grant emergency use authorization to the two companies that recently applied. 

“I think these drugs will make a meaningful difference for people who are the highest risk of having a bad outcome,” Gottlieb said on “Closing Bell.” “But this is not going to end the epidemic. This is not going to be widely available to everyone,” he added. 

Priority would probably be given to Covid-19 patients who are over the age of 65, given they are more likely to become severely ill or

Read More
By [email protected]_84

Remdesivir Effective, Well-Tolerated in Final Trial Report

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

A final report from the multinational placebo-controlled ACTT-1 trial confirms that remdesivir is effective and well tolerated for shortening the time to recovery from COVID-19 infection.

In May 2020, remdesivir received Food and Drug Administration approval for emergency treatment of severe COVID-19 on the basis of a preliminary report on this trial. In August 2020, the FDA expanded the indication to include all hospitalized adult and pediatric patients with suspected or laboratory-confirmed COVID-19 infection irrespective of severity.

“Our findings were consistent with the findings of the preliminary report: a 10-day course of remdesivir was superior to placebo in the treatment of hospitalized patients with COVID-19,” reported a team of investigators led by John H. Beigel, MD, of the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, in the New

Read More
By [email protected]_84

Coronavirus infections ‘increasing rapidly’ as cases nearly double in a week to 224k

People wear PPE masks and face coverings as they walk through the city centre in Manchester, north west England on October 8, 2020. - Pubs and restaurants in coronavirus hotspots look set to face fresh restrictions after Downing Street said new data suggests there is "significant" transmission taking place in hospitality settings. A "range of measures" is being looked at, with a particular focus on northern England, where it says infection rates are rising fastest. (Photo by Oli SCARFF / AFP) (Photo by OLI SCARFF/AFP via Getty Images)
Coronavirus infections in England have risen, a major study has found. (Oli Scarff/AFP via Getty Images)
  • Nearly 250,000 people have COVID-19 in England, new study suggests

  • ONS infection survey estimates total cases have nearly doubled in a week

  • One in 240 people in country thought to be infected

  • Visit the Yahoo homepage for more stories

There are nearly a quarter of a million people in England with the coronavirus, a major study has found.

An Office for National Statistics (ONS) infection survey, released on Friday, suggested there were 224,400 people with COVID-19 between between 25 September and 1 October, the latest dates for which data is available.

This was nearly double the 116,600 people with COVID the week before.

It means about one in 240 people in the country are thought to be infected.

The survey, which tests thousands of people in English homes whether they have symptoms or not,

Read More